We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





New COVID-19 Test Shows Patients with Suppressed Immune Systems Can Also Achieve Good Immune Response to SARS-CoV-2

By LabMedica International staff writers
Posted on 31 Aug 2020
A new test that provides information on the immune response to the novel coronavirus in patients who need to take immunosuppressive drugs has shown that these patients can achieve a good immune response to SARS-CoV-2 despite immunosuppression.

A research team from the University Hospital at Ruhr-Universität Bochum (RUB Bochum, Germany) has developed the test which can be used to adapt immunosuppressive therapy individually during a COVID-19 infection, such as following an organ transplantation. More...
The test is of great clinical relevance for transplant patients as it provides information that goes far beyond a pure antibody test.

Transplant patients are affected in several ways: in addition to the chronic illness that led to organ failure and subsequent transplantation, transplant patients need to take medications that suppress the defenses of their own immune system. Chronically ill patients with impaired immune defenses have an increased risk of suffering from a severe COVID-19 infection. It was previously unknown whether patients could develop a sufficient reaction against the new coronavirus under the influence of immunosuppressive drugs.

With the help of the test, the team demonstrated that transplant patients are very capable of achieving a good immune response despite immunosuppression. In addition to high antibody titres, large quantities of T lymphocytes, which are responsible for killing infected cells, were found in the current case study.

“Until now, it has not been known whether our transplant patients are capable of forming a sufficient immune response to the new coronavirus,” said Professor Timm Westhoff, Director of Medical Clinic I at Marien Hospital Herne, who led the team of researchers. “The data obtained help us to deal with immunosuppression during the current pandemic. The test allows us to individually adjust immunosuppression when a patient is suffering from COVID-19.”

Related Links:
Ruhr-Universität Bochum


Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Online QC Software
Acusera 24•7
All-in-One Molecular System
AIO M160
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.